NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Oil & Gas, Basic Materials and Technology sectors led shares lower. At the close in NYSE, the...
Akari Therapeutics, Plc (NASDAQ:AKTX) announced that the FDA has granted an orphan drug designation to its lead pipeline candidate nomacopan for the treatment of bullous...
It was a low-key week for the biotech sector, with updates from only a few players. While Regeneron (NASDAQ:REGN) won a long-standing duel against rival Amgen (NASDAQ:AMGN) ,...
Akari Therapeutics, Plc (NASDAQ:AKTX) announced that the FDA has granted an orphan drug designation to its lead pipeline candidate nomacopan for the treatment of hematopoietic...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||5H||Current|
|Bullish Engulfing||1M||2||Aug 19|
|Bullish doji Star||1D||2||Oct 11, 2019|
|Tri-Star Bearish||30||2||Oct 15, 2019 02:30PM|
|Bank of America||29.73||30.24||29.11||+0.59||+2.02%||78.20M||15:59:59|
|Viking Therapeutics Inc||6.620||6.650||6.385||+0.220||+3.44%||1.01M||15:59:59|
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.